We previously demonstrated that DAB-Tf dendriplexes encoding TNFα, TRAIL, and IL-12 could result in prostate tumor regression (Al Robaian et al., 2014), but their therapeutic efficacy was lower than with DAB-Lf dendriplexes (respectively, 60% and 10% PC-3 tumor suppression following treatment with DAB-Tf dendriplexes encoding TNFα and TRAIL, but 70 and 40% tumor suppression when replacing Tf by Lf). Here, TF is linked to prostate neoplasm.